Logo image of INBX

INHIBRX BIOSCIENCES INC (INBX) Stock Fundamental Analysis

NASDAQ:INBX - Nasdaq - US45720N1037 - Common Stock - Currency: USD

11.3  +0.2 (+1.8%)

Fundamental Rating

4

INBX gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 563 industry peers in the Biotechnology industry. While INBX has a great health rating, there are worries on its profitability. While showing a medium growth rate, INBX is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

INBX had positive earnings in the past year.
In the past year INBX has reported a negative cash flow from operations.
INBX had negative earnings in 4 of the past 5 years.
In the past 5 years INBX always reported negative operating cash flow.
INBX Yearly Net Income VS EBIT VS OCF VS FCFINBX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B 1.5B

1.2 Ratios

With an excellent Return On Assets value of 933.56%, INBX belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
INBX has a Return On Equity of 1263.30%. This is amongst the best in the industry. INBX outperforms 100.00% of its industry peers.
Industry RankSector Rank
ROA 933.56%
ROE 1263.3%
ROIC N/A
ROA(3y)268.02%
ROA(5y)139.35%
ROE(3y)153.62%
ROE(5y)40.8%
ROIC(3y)N/A
ROIC(5y)N/A
INBX Yearly ROA, ROE, ROICINBX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 1K

1.3 Margins

The Profit Margin of INBX (843786.00%) is better than 100.00% of its industry peers.
The Operating Margin and Gross Margin are not available for INBX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) 843786%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
INBX Yearly Profit, Operating, Gross MarginsINBX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 200K 400K 600K 800K

More info and screens

7

2. Health

2.1 Basic Checks

INBX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for INBX has been reduced compared to 1 year ago.
INBX has less shares outstanding than it did 5 years ago.
There is no outstanding debt for INBX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
INBX Yearly Shares OutstandingINBX Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
INBX Yearly Total Debt VS Total AssetsINBX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

Based on the Altman-Z score of -4.03, we must say that INBX is in the distress zone and has some risk of bankruptcy.
INBX's Altman-Z score of -4.03 is in line compared to the rest of the industry. INBX outperforms 44.94% of its industry peers.
INBX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -4.03
ROIC/WACCN/A
WACC11.31%
INBX Yearly LT Debt VS Equity VS FCFINBX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

INBX has a Current Ratio of 3.94. This indicates that INBX is financially healthy and has no problem in meeting its short term obligations.
INBX's Current ratio of 3.94 is in line compared to the rest of the industry. INBX outperforms 46.36% of its industry peers.
INBX has a Quick Ratio of 3.94. This indicates that INBX is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of INBX (3.94) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.94
Quick Ratio 3.94
INBX Yearly Current Assets VS Current LiabilitesINBX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

4

3. Growth

3.1 Past

INBX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 2448.11%, which is quite impressive.
Looking at the last year, INBX shows a very negative growth in Revenue. The Revenue has decreased by -88.91% in the last year.
INBX shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -56.75% yearly.
EPS 1Y (TTM)2448.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-78.61%
Revenue 1Y (TTM)-88.91%
Revenue growth 3Y-69.76%
Revenue growth 5Y-56.75%
Sales Q2Q%-93.88%

3.2 Future

The Earnings Per Share is expected to decrease by -62.23% on average over the next years. This is quite bad
INBX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 449.31% yearly.
EPS Next Y-109.94%
EPS Next 2Y-43.73%
EPS Next 3Y-26.08%
EPS Next 5Y-62.23%
Revenue Next Year-100%
Revenue Next 2Y555.74%
Revenue Next 3Y1400.52%
Revenue Next 5Y449.32%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
INBX Yearly Revenue VS EstimatesINBX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2026 2027 2028 2029 2030 2031 200M 400M 600M
INBX Yearly EPS VS EstimatesINBX Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 20 40 60 80 100

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

INBX is valuated cheaply with a Price/Earnings ratio of 0.10.
100.00% of the companies in the same industry are more expensive than INBX, based on the Price/Earnings ratio.
The average S&P500 Price/Earnings ratio is at 23.99. INBX is valued rather cheaply when compared to this.
The Forward Price/Earnings Ratio is negative for INBX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE 0.1
Fwd PE N/A
INBX Price Earnings VS Forward Price EarningsINBX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
INBX Per share dataINBX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 40 60 80 100

4.3 Compensation for Growth

INBX's earnings are expected to decrease with -26.08% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-43.73%
EPS Next 3Y-26.08%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for INBX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

INHIBRX BIOSCIENCES INC

NASDAQ:INBX (5/8/2025, 10:46:59 AM)

11.3

+0.2 (+1.8%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-17 2025-03-17/amc
Earnings (Next)N/A N/A
Inst Owners62.61%
Inst Owner Change-20.15%
Ins Owners15.64%
Ins Owner Change0%
Market Cap163.62M
Analysts45.71
Price Target15.3 (35.4%)
Short Float %7.97%
Short Ratio6.92
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)6.32%
Min EPS beat(2)-4.97%
Max EPS beat(2)17.6%
EPS beat(4)2
Avg EPS beat(4)873.52%
Min EPS beat(4)-35.75%
Max EPS beat(4)3517.21%
EPS beat(8)2
Avg EPS beat(8)423.89%
EPS beat(12)3
Avg EPS beat(12)277.18%
EPS beat(16)7
Avg EPS beat(16)209.8%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-37.86%
EPS NY rev (1m)0%
EPS NY rev (3m)-22.45%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 0.1
Fwd PE N/A
P/S 818.12
P/FCF N/A
P/OCF N/A
P/B 1.22
P/tB 1.22
EV/EBITDA N/A
EPS(TTM)118.11
EY1045.22%
EPS(NY)-11.74
Fwd EYN/A
FCF(TTM)-13.61
FCFYN/A
OCF(TTM)-13.43
OCFYN/A
SpS0.01
BVpS9.23
TBVpS9.23
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 933.56%
ROE 1263.3%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 843786%
GM N/A
FCFM N/A
ROA(3y)268.02%
ROA(5y)139.35%
ROE(3y)153.62%
ROE(5y)40.8%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 113.65%
Cap/Sales 1298.5%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.94
Quick Ratio 3.94
Altman-Z -4.03
F-Score4
WACC11.31%
ROIC/WACCN/A
Cap/Depr(3y)185.13%
Cap/Depr(5y)152.08%
Cap/Sales(3y)528.39%
Cap/Sales(5y)321.52%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)2448.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-78.61%
EPS Next Y-109.94%
EPS Next 2Y-43.73%
EPS Next 3Y-26.08%
EPS Next 5Y-62.23%
Revenue 1Y (TTM)-88.91%
Revenue growth 3Y-69.76%
Revenue growth 5Y-56.75%
Sales Q2Q%-93.88%
Revenue Next Year-100%
Revenue Next 2Y555.74%
Revenue Next 3Y1400.52%
Revenue Next 5Y449.32%
EBIT growth 1Y-51.19%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year72.68%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y0.45%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-0.57%
OCF growth 3YN/A
OCF growth 5YN/A